Residency · Residency · Pediatrics

Adolescent Contraception and Reproductive Health

Introduction

Approximately 40% of U.S. high school students report having had sexual intercourse, yet adolescents face disproportionate rates of unintended pregnancy and sexually transmitted infections (STIs). Effective contraceptive counseling is a core competency in pediatric and adolescent medicine. A patient-centered, nonjudgmental approach that respects adolescent autonomy and addresses barriers to access is essential. The American Academy of Pediatrics recommends that pediatricians provide comprehensive reproductive health services including contraception counseling, STI screening, and pregnancy options counseling.

Developmental and Legal Considerations

Adolescent cognitive development influences contraceptive choice: concrete thinkers (younger adolescents) may struggle with daily pill adherence, so long-acting methods that reduce user-dependent failure are particularly advantageous. Most states allow minors to consent to contraceptive services without parental involvement, though specific laws vary by jurisdiction. Title X clinics provide confidential family planning services regardless of age, insurance status, or ability to pay. Confidentiality should be reviewed carefully, including the implications of EOB and insurance billing, as some adolescents may prefer clinic-dispensed methods to avoid insurance claims visible to parents.

Contraceptive Counseling Framework

Tiered Effectiveness Approach

Methods should be presented in order of effectiveness while respecting patient preference. Shared decision-making should address efficacy, side effects, non-contraceptive benefits, and fit with the adolescent's lifestyle. LARC-first counseling (long-acting reversible contraception) is recommended by ACOG and AAP as first-line for adolescents.

Assessing Contraceptive Needs

The assessment should include sexual activity history (current and anticipated), menstrual history (cycle regularity, dysmenorrhea, heavy bleeding), and medical history with particular attention to migraines with aura, VTE risk, and seizure medications (enzyme-inducing drugs reduce hormonal contraceptive efficacy). The CDC Medical Eligibility Criteria (MEC) should be used to assess the safety of specific methods.

Contraceptive Methods

Tier 1: Long-Acting Reversible Contraception (LARC)

Intrauterine devices (IUDs) include the levonorgestrel IUD (Mirena, Kyleena, Liletta), which is effective for 3-8 years depending on the device, reduces menstrual bleeding and dysmenorrhea, and has a failure rate less than 0.2%. The copper IUD (Paragard) is hormone-free, effective for 10 years, may increase menstrual bleeding, and can serve as emergency contraception if placed within 5 days of unprotected intercourse. IUDs are safe for nulliparous adolescents and do not increase the risk of infertility or pelvic inflammatory disease beyond the first 20 days post-insertion.

The subdermal implant (Nexplanon) is an etonogestrel device that is the most effective reversible contraceptive, with a failure rate of 0.05%. It is effective for 3 years and placed in the upper arm. The most common side effect is irregular bleeding, which should be discussed extensively before insertion. Because it contains no estrogen, it is safe for patients with migraines with aura or VTE risk.

Tier 2: Short-Acting Hormonal Methods

Depot medroxyprogesterone acetate (DMPA/Depo-Provera) is an IM injection given every 13 weeks with a typical use failure rate of 6%. It is convenient and private and reduces dysmenorrhea and endometriosis symptoms. The FDA black box warning regarding bone mineral density loss should be weighed against benefits in adolescents, though the loss is reversible with discontinuation and there is no evidence of increased fracture risk. A subcutaneous self-injection formulation (Depo-SubQ Provera) is also available.

Combined oral contraceptives (COCs) contain estrogen plus progestin and have a typical use failure rate of 9%. Non-contraceptive benefits include cycle regulation, reduced dysmenorrhea, acne improvement, and reduced ovarian and endometrial cancer risk. Absolute contraindications (MEC category 4) include migraines with aura, VTE history, smoking 15 or more cigarettes per day in patients over 35, and uncontrolled hypertension.

The transdermal patch (Xulane) is applied weekly for 3 weeks with 1 week off, has similar efficacy and side effects to COCs, and may be less effective in patients over 90 kg. The vaginal ring (NuvaRing, Annovera) is placed for 3 weeks and removed for 1 week, with Annovera being reusable for 1 year.

Tier 3: Barrier and Behavioral Methods

Male condoms have an 18% typical use failure rate for pregnancy but are essential for STI prevention, making dual method use (condoms plus a hormonal method) the recommended approach. Female condoms (internal condoms) can be inserted up to 8 hours before intercourse. Fertility awareness-based methods require high motivation and regular cycles and are not recommended as the primary method for most adolescents. Withdrawal has a 22% typical use failure rate and is not recommended as a sole method.

<image>Tiered effectiveness chart of contraceptive methods arranged from most effective (implant and IUDs at the top) to least effective (withdrawal and spermicide at the bottom), showing typical use failure rates, duration of action, and key advantages for adolescents</image>

Emergency Contraception

Levonorgestrel (Plan B) is available over-the-counter without age restriction, is most effective within 72 hours (can be used up to 120 hours), is given as a single 1.5 mg dose, and is less effective in patients over 75 kg. Ulipristal acetate (ella) requires a prescription, is effective up to 120 hours, is more effective than levonorgestrel especially at 72-120 hours and in higher-weight patients, and works by delaying ovulation. The copper IUD is the most effective emergency contraception with a failure rate less than 0.1%, is effective up to 5 days post-unprotected intercourse, and provides ongoing contraception. Emergency contraception is not an abortifacient -- it works by delaying or inhibiting ovulation. Advance prescriptions should be provided so adolescents have emergency contraception available when needed.

STI Screening and Prevention

Screening Recommendations (CDC/USPSTF)

All sexually active females under 25 should be screened annually for chlamydia and gonorrhea, with males screened in high-prevalence settings, using NAAT (nucleic acid amplification test) on urine or vaginal/cervical swab. HIV screening should occur at least once for all adolescents aged 15-18 years, with more frequent testing for those at higher risk. Syphilis and hepatitis B/C screening is risk-based. HPV vaccination is recommended for all adolescents starting at age 9-12, with a 2-dose series if started before age 15 and a 3-dose series if started at 15 or older. Extragenital screening with pharyngeal and rectal NAAT for gonorrhea and chlamydia should be performed in patients with oral or anal sexual contact.

Common STIs in Adolescents

Chlamydia is the most common bacterial STI, is often asymptomatic, and is treated with doxycycline 100 mg twice daily for 7 days (preferred over azithromycin per 2021 CDC guidelines). Gonorrhea is treated with ceftriaxone 500 mg IM once (1 g if greater than 150 kg), with co-treatment for chlamydia if not tested. HPV is the most common STI overall, with most infections clearing spontaneously; high-risk strains cause cervical cancer, and vaccination is the primary prevention strategy. HSV is diagnosed clinically and confirmed by PCR or viral culture, with treatment using acyclovir or valacyclovir. Expedited partner therapy (EPT) is legal in most states for chlamydia and gonorrhea.

<image>Anatomical diagram showing common STI presentations in adolescents including cervicitis, urethritis, pharyngeal infection, and genital ulcers, with recommended screening tests (NAAT) and treatment regimens for chlamydia, gonorrhea, and syphilis</image>

Pregnancy Options Counseling

Pregnancy is confirmed with urine or serum beta-hCG, and gestational age is estimated using the last menstrual period and ultrasound. All options should be presented in a nondirective, nonjudgmental manner: continuation of pregnancy with parenting, continuation of pregnancy with adoption or placement, and pregnancy termination with information about access, safety, and referral provided regardless of personal beliefs. Safety assessment should include intimate partner violence screening, housing stability, and support systems. Early prenatal care or termination referral should be provided as appropriate. Adolescent pregnancy is associated with higher rates of preterm birth, low birth weight, and postpartum depression, requiring close monitoring.

<image>Decision-support flowchart for adolescent pregnancy options counseling showing the nondirective counseling approach with information pathways for each option (parenting, adoption, termination), associated referrals, and support services</image>

Clinical Pearls

LARC methods (IUDs and implants) are the most effective contraceptives and are safe and recommended as first-line for adolescents regardless of parity. Condoms should always be recommended in addition to hormonal contraception, as dual method use protects against both pregnancy and STIs. Adolescents can consent to contraceptive services in most jurisdictions, and clinicians should know their state's minor consent laws. All sexually active adolescent females should be screened annually for chlamydia and gonorrhea, as most infections are asymptomatic. Emergency contraception should be discussed proactively, with advance prescriptions empowering adolescents to act quickly when needed.

References

1. Committee on Adolescence, American Academy of Pediatrics. Contraception for Adolescents. Pediatrics. 2014;134(4):e1244-e1256.
2. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
3. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
4. Ott MA, Sucato GS, Committee on Adolescence. Contraception for Adolescents. Pediatrics. 2014;134(4):e1257-e1281.

Read this lecture as Markdown